Anemia, diabetes, and chronic kidney disease

Uzma Mehdi, Robert D. Toto

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Anemia is common and contributes to both poor QOL and increased risk for adverse outcomes including death. Treatment of anemia improves QOL; however, thus far, evidence is lacking for a benefit of anemia treatment on progression of kidney disease and cardiovascular outcomes. The NKF recommends that physicians consider treating anemia in patients with diabetes and kidney disease when Hb is <11 g/dl in patients. Further, they recommend a Hb target of 11-12 g/dl, not to exceed 13 g/dl, when using an ESA as part of the therapeutic regimen for managing anemia. Currently available ESA combined with iron supplementation can be used safely and effectively to achieve this goal. However, available clinical trial evidence leaves sufficient uncertainty regarding the optimal Hb target and ESA dose for a given individual. For this reason, the NKF recommends individualizing treatment of anemia with ESA. Additional randomized clinical trials are needed to more precisely define these parameters for an individual patient. Future studies are also needed to elaborate the mechanisms of anemia in patients with diabetes and CKD including the role of iron metabolism, inflammation, and resistance.

Original languageEnglish (US)
Pages (from-to)1320-1326
Number of pages7
JournalDiabetes Care
Volume32
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Chronic Renal Insufficiency
Anemia
Kidney Diseases
Iron
Therapeutics
Uncertainty
Randomized Controlled Trials
Clinical Trials
Inflammation
Physicians

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Anemia, diabetes, and chronic kidney disease. / Mehdi, Uzma; Toto, Robert D.

In: Diabetes Care, Vol. 32, No. 7, 07.2009, p. 1320-1326.

Research output: Contribution to journalArticle

Mehdi, Uzma ; Toto, Robert D. / Anemia, diabetes, and chronic kidney disease. In: Diabetes Care. 2009 ; Vol. 32, No. 7. pp. 1320-1326.
@article{30d830141c1c402483752e046a3cee86,
title = "Anemia, diabetes, and chronic kidney disease",
abstract = "Anemia is common and contributes to both poor QOL and increased risk for adverse outcomes including death. Treatment of anemia improves QOL; however, thus far, evidence is lacking for a benefit of anemia treatment on progression of kidney disease and cardiovascular outcomes. The NKF recommends that physicians consider treating anemia in patients with diabetes and kidney disease when Hb is <11 g/dl in patients. Further, they recommend a Hb target of 11-12 g/dl, not to exceed 13 g/dl, when using an ESA as part of the therapeutic regimen for managing anemia. Currently available ESA combined with iron supplementation can be used safely and effectively to achieve this goal. However, available clinical trial evidence leaves sufficient uncertainty regarding the optimal Hb target and ESA dose for a given individual. For this reason, the NKF recommends individualizing treatment of anemia with ESA. Additional randomized clinical trials are needed to more precisely define these parameters for an individual patient. Future studies are also needed to elaborate the mechanisms of anemia in patients with diabetes and CKD including the role of iron metabolism, inflammation, and resistance.",
author = "Uzma Mehdi and Toto, {Robert D.}",
year = "2009",
month = "7",
doi = "10.2337/dc08-0779",
language = "English (US)",
volume = "32",
pages = "1320--1326",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Anemia, diabetes, and chronic kidney disease

AU - Mehdi, Uzma

AU - Toto, Robert D.

PY - 2009/7

Y1 - 2009/7

N2 - Anemia is common and contributes to both poor QOL and increased risk for adverse outcomes including death. Treatment of anemia improves QOL; however, thus far, evidence is lacking for a benefit of anemia treatment on progression of kidney disease and cardiovascular outcomes. The NKF recommends that physicians consider treating anemia in patients with diabetes and kidney disease when Hb is <11 g/dl in patients. Further, they recommend a Hb target of 11-12 g/dl, not to exceed 13 g/dl, when using an ESA as part of the therapeutic regimen for managing anemia. Currently available ESA combined with iron supplementation can be used safely and effectively to achieve this goal. However, available clinical trial evidence leaves sufficient uncertainty regarding the optimal Hb target and ESA dose for a given individual. For this reason, the NKF recommends individualizing treatment of anemia with ESA. Additional randomized clinical trials are needed to more precisely define these parameters for an individual patient. Future studies are also needed to elaborate the mechanisms of anemia in patients with diabetes and CKD including the role of iron metabolism, inflammation, and resistance.

AB - Anemia is common and contributes to both poor QOL and increased risk for adverse outcomes including death. Treatment of anemia improves QOL; however, thus far, evidence is lacking for a benefit of anemia treatment on progression of kidney disease and cardiovascular outcomes. The NKF recommends that physicians consider treating anemia in patients with diabetes and kidney disease when Hb is <11 g/dl in patients. Further, they recommend a Hb target of 11-12 g/dl, not to exceed 13 g/dl, when using an ESA as part of the therapeutic regimen for managing anemia. Currently available ESA combined with iron supplementation can be used safely and effectively to achieve this goal. However, available clinical trial evidence leaves sufficient uncertainty regarding the optimal Hb target and ESA dose for a given individual. For this reason, the NKF recommends individualizing treatment of anemia with ESA. Additional randomized clinical trials are needed to more precisely define these parameters for an individual patient. Future studies are also needed to elaborate the mechanisms of anemia in patients with diabetes and CKD including the role of iron metabolism, inflammation, and resistance.

UR - http://www.scopus.com/inward/record.url?scp=67650082797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650082797&partnerID=8YFLogxK

U2 - 10.2337/dc08-0779

DO - 10.2337/dc08-0779

M3 - Article

C2 - 19564475

AN - SCOPUS:67650082797

VL - 32

SP - 1320

EP - 1326

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 7

ER -